$SLRX
Salarius Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000161521924000089 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $869.2K
YoY Change -42.05%
% of Gross Profit
Research & Development $137.2K
YoY Change -86.76%
% of Gross Profit
Depreciation & Amortization $1.110K
YoY Change -88.9%
% of Gross Profit
Operating Expenses $1.006M
YoY Change -60.25%
Operating Profit -$1.006M
YoY Change -60.25%
Interest Expense $34.35K
YoY Change -61.56%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$972.1K
YoY Change -60.16%
Income Tax
% Of Pretax Income
Net Earnings -$972.1K
YoY Change -60.2%
Net Earnings / Revenue
Basic Earnings Per Share -$0.76
Diluted Earnings Per Share -$0.76
COMMON SHARES
Basic Shares Outstanding 1.441M shares 1.441M shares
Diluted Shares Outstanding 1.282M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.284M
YoY Change -56.79%
Cash & Equivalents $3.284M
Short-Term Investments
Other Short-Term Assets $119.0K
YoY Change 43.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.823M
YoY Change -54.08%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $36.52K
YoY Change -54.6%
Total Long-Term Assets $36.52K
YoY Change -54.6%
TOTAL ASSETS
Total Short-Term Assets $3.823M
Total Long-Term Assets $36.52K
Total Assets $3.859M
YoY Change -54.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $165.8K
YoY Change -84.77%
Accrued Expenses $439.9K
YoY Change -45.01%
Deferred Revenue
YoY Change
Short-Term Debt $328.9K
YoY Change -34.23%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $934.6K
YoY Change -59.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $934.6K
Total Long-Term Liabilities $0.00
Total Liabilities $934.6K
YoY Change -59.73%
SHAREHOLDERS EQUITY
Retained Earnings -$80.46M
YoY Change 6.62%
Common Stock $144.00
YoY Change -63.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.925M
YoY Change
Total Liabilities & Shareholders Equity $3.859M
YoY Change -54.08%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$972.1K
YoY Change -60.2%
Depreciation, Depletion And Amortization $1.110K
YoY Change -88.9%
Cash From Operating Activities -$1.357M
YoY Change -63.73%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.368M
YoY Change -751.37%
NET CHANGE
Cash From Operating Activities -1.357M
Cash From Investing Activities
Cash From Financing Activities 1.368M
Net Change In Cash 11.21K
YoY Change -100.28%
FREE CASH FLOW
Cash From Operating Activities -$1.357M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
801395 shares
us-gaap Net Income Loss
NetIncomeLoss
-4111844 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3318 usd
us-gaap Share Based Compensation
ShareBasedCompensation
439462 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Central Index Key
EntityCentralIndexKey
0001615219
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
SALARIUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5087339
dei Entity Address Address Line1
EntityAddressAddressLine1
2450 Holcombe Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite X
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77021
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
804-9144
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
SLRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1441157 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3284029 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5899910 usd
CY2024Q3 us-gaap Liabilities
Liabilities
934581 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1299241 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
144 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83384124 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80459685 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76347841 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2924583 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5287282 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3859164 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6586523 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
137234 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1036354 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
594683 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7113794 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
869237 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1495831 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3650920 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4810449 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1006471 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2532185 usd
us-gaap Operating Expenses
OperatingExpenses
4245603 usd
us-gaap Operating Expenses
OperatingExpenses
11924243 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1006471 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4245603 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11924243 usd
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
34350 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
89369 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
133759 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
263346 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-972121 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2442816 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-4111844 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11660897 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-972121 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2442816 usd
us-gaap Net Income Loss
NetIncomeLoss
-4111844 usd
us-gaap Net Income Loss
NetIncomeLoss
-11660897 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.21
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-30.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-30.71
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
801395 shares
us-gaap Share Based Compensation
ShareBasedCompensation
222685 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-506888 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-437052 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
33186 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3782819 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6809061 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4525847 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12106435 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3284029 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7580588 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
189.36
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M14D
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Amendment Flag
AmendmentFlag
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1281869 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
469254 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-671848 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1769690 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-635067 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11334908 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
538617 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
619763 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6519673 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
36518 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
66850 usd
CY2024Q3 us-gaap Assets
Assets
3859164 usd
CY2023Q4 us-gaap Assets
Assets
6586523 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
165801 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
602853 usd
CY2024Q3 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
439931 usd
CY2023Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
406745 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
328849 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
289643 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
492304 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
492304 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
469254 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
379693 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
379693 shares
us-gaap Net Income Loss
NetIncomeLoss
-11660897 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8946 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5899910 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
59 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
112658 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2442816 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6083703 usd
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.125
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.125
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.125
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y6M
CY2024Q3 us-gaap Assets Current
AssetsCurrent
3822646 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1441157 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1441157 shares
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
81635074 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2532185 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.13
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1281869 shares
flks Grant Receivable Write Off
GrantReceivableWriteOff
0 usd
flks Grant Receivable Write Off
GrantReceivableWriteOff
130000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1480490 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1526460 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
6920530 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
359522 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
111469 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1166938 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2615881 usd
us-gaap Interest Paid Net
InterestPaidNet
12064 usd
us-gaap Interest Paid Net
InterestPaidNet
6799 usd
flks Stock Issuance Costs Accrued And Amortized
StockIssuanceCostsAccruedAndAmortized
0 usd
flks Stock Issuance Costs Accrued And Amortized
StockIssuanceCostsAccruedAndAmortized
0 usd
flks Insurance Premium Financed By Note Payable
InsurancePremiumFinancedByNotePayable
398728 usd
flks Insurance Premium Financed By Note Payable
InsurancePremiumFinancedByNotePayable
570560 usd
flks Insurance Premium Financed By Note Payable
InsurancePremiumFinancedByNotePayable
570560 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10384608 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
311681 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
203345 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5340773 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5558861 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6608790 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
123459 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3877308 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8413802 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5287282 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
77508 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1715290 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3649538 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
65080 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
85168 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1424433 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2375353 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1461342 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
60009 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-972121 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2924583 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1047070 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1370516 shares
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
419602 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
468495 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
119015 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
151268 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
538617 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
619763 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
300000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
300000 usd
CY2016Q2 flks Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
18700000 usd
CY2023 flks Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
16100000 usd
CY2024Q3 flks Revenue From Grants Revenue Sharing Payments Continued Payments Percent Of Net Sales
RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
0.01
CY2020Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
236.40
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y6M
CY2022Q2 flks Warrants And Rights Exercisable Term
WarrantsAndRightsExercisableTerm
P6M
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1015385 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1355600 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
21125 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
100000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0425
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0461
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.0607
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.2331
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13391 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13391 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
189.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M14D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8893 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
226.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M9D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11164 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
190.24
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M3D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
21125 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.02
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
735 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
31554 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
66.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9086 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
206.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M28D
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
100000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
400000 usd

Files In Submission

Name View Source Status
0001615219-24-000089-index-headers.html Edgar Link pending
0001615219-24-000089-index.html Edgar Link pending
0001615219-24-000089.txt Edgar Link pending
0001615219-24-000089-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
flks-20240930.htm Edgar Link pending
flks-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slrx20240930ex-311.htm Edgar Link pending
slrx20240930ex-312.htm Edgar Link pending
slrx20240930ex-321.htm Edgar Link pending
flks-20240930_cal.xml Edgar Link unprocessable
flks-20240930_def.xml Edgar Link unprocessable
flks-20240930_lab.xml Edgar Link unprocessable
flks-20240930_pre.xml Edgar Link unprocessable
flks-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable